CHEMED CORP: insider trades · United States · SEC (Form 4)

About CHEMED CORP

Chemed Corp. (NYSE: CHE) is a U.S.-listed company traded on the New York Stock Exchange in the United States, with corporate headquarters in Cincinnati, Ohio. The group is best understood as a two-platform services company built around VITAS Healthcare and Roto-Rooter. Chemed was incorporated in Delaware in 1970 as a subsidiary of W.R. Grace & Co., succeeded to the Special Products Group in 1971, and became independent in 1982. That history matters: Chemed remains a capital-allocation driven holding company with decentralized operating businesses and limited overlap between the two segments. VITAS is the company’s healthcare platform and one of the largest providers of hospice and end-of-life care in the United States. Its model focuses on non-curative care designed to improve patient comfort and support families through medical, nursing, social, and spiritual services. Roto-Rooter is the second pillar and a leading North American brand in plumbing, drain cleaning, water cleanup, and related emergency restoration services. The two businesses give Chemed a distinct profile: a regulated, reimbursement-sensitive healthcare franchise paired with a more consumer- and property-services-oriented operation that tends to benefit from recurring emergency demand. From a competitive standpoint, VITAS benefits from scale in a market where operational execution, referral networks, staffing, and reimbursement management are critical. Roto-Rooter enjoys strong brand recognition and broad service reach across residential, commercial, and municipal customers. Together, the businesses provide geographic diversification within the U.S. and exposure to different demand drivers, although the company remains primarily domestic. Chemed’s earnings can be influenced by Medicare cap mechanics in hospice, labor costs, and service mix, while Roto-Rooter’s performance is more tied to service volumes, weather patterns, housing-related activity, and pricing. Recent developments underscore a shareholder-return focus. Chemed reported first-quarter 2026 results on April 23, 2026, and its investor-relations page shows ongoing participation in healthcare conferences during May 2026. Most notably, on May 13, 2026, the board authorized an additional $300 million for share repurchases, reinforcing management’s willingness to return excess capital to shareholders. For investors, Chemed offers an unusual mix of defensive healthcare cash generation and service-led operating leverage, making it a differentiated U.S. NYSE name rather than a pure-play healthcare stock.